CJC-1295, Ipamorelin, and Tesamorelin: Three Different Research Stories

CJC-1295, ipamorelin, and tesamorelin often appear in the same conversation because they interact with signals involved in growth hormone release. Their human studies asked remarkably different questions. One measured hormones. One measured recovery after bowel surgery. One measured fat around internal organs in people living with HIV.

CJC-1295: A signal you can measure

In placebo-controlled studies of healthy adults, the long-acting CJC-1295 formulation raised blood levels of growth hormone and IGF-1, a hormone involved in some of growth hormone’s effects. Researchers could follow the change for several days. That’s a useful finding about the activity of the studied formulation. It doesn’t tell us whether participants built muscle, slept better, or recovered faster from exercise. The studies weren’t designed to measure those outcomes. 1

Ipamorelin: A different clinical question

Ipamorelin mimics some of the activity of ghrelin, a hormone involved in gut signaling as well as growth hormone release. One randomized trial asked whether it helped people resume eating after bowel surgery. The trial did not find a statistically clear difference in its main measure, the time until participants could tolerate a solid meal. That’s valuable information about the proposed use. It also illustrates how much gets lost when a headline only says that a peptide “has human trials.” 2

Tesamorelin: A measurable result for a defined group

A Canadian-led analysis combined two placebo-controlled trials in people with HIV and excess abdominal fat. Tesamorelin reduced visceral fat, the fat that surrounds internal organs, compared with placebo. The studies looked at a particular health issue in a defined group of people. Their finding tells us about that population and outcome rather than about general weight loss or changes in appearance. 3

How to compare the claims you hear

Ask what the researchers counted as success. A lab result can show that a molecule is doing something biologically. A change in symptoms or daily function helps answer whether that activity translates into a benefit. Different measures can each be useful, as long as the conclusion fits the evidence.

The same applies to a combination label: if the paper tested CJC-1295 or ipamorelin separately, it can’t answer what happens when someone combines them. Peptide Medicines, Compounding, and Supplements offers more context on why formulations matter.